SCHEMBL5651763

SCHEMBL5651763

CC(C)COC(=O)NCCC[C@H](NC(=O)c1cc2ccccc2o1)C(=O)NCCc1ccc(C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 3/20 0.61
TAS1R3 Q7RTX0 3/20 0.49
TAS1R1 Q7RTX1 3/20 0.49
MMP8 P22894 2/20 0.46
MCHR1 Q99705 1/20 0.44
NAMPT P43490 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.42
THRB P10828 1/20 0.42
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NMBR P28336 1/20 0.41
MAOB P27338 1/20 0.41
CPB1 P15086 1/20 0.41
CPB2 Q96IY4 1/20 0.41
CTSK P43235 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5657127 0.93 PTGER4 (0.58) PTGER4TAS1R3TAS1R1MMP8MCHR1
SCHEMBL5655171 0.90 PTGER4 (0.75) PTGER4TAS1R3TAS1R1MCHR1NPC1
SCHEMBL5654281 0.88 PTGER4 (0.59) PTGER4MMP8MCHR1NAMPTNPC1
SCHEMBL5653856 0.86 PTGER4 (0.62) PTGER4TAS1R3TAS1R1MMP8MCHR1
SCHEMBL5653684 0.85 PTGER4 (0.72) PTGER4TAS1R3TAS1R1MMP8MCHR1
SCHEMBL5654297 0.84 PTGER4 (0.58) PTGER4MMP8MCHR1NAMPTNPC1
SCHEMBL5654420 0.83 PTGER4 (0.74) PTGER4TAS1R3TAS1R1MCHR1NAMPT
SCHEMBL5653410 0.83 PTGER4 (0.55) PTGER4TAS1R3TAS1R1MMP8MCHR1
SCHEMBL5655307 0.83 PTGER4 (0.55) PTGER4TAS1R3TAS1R1MMP8MCHR1
SCHEMBL5654830 0.82 PTGER4 (0.56) PTGER4TAS1R3TAS1R1MMP8MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists ASTELLAS PHARMA INC. (JP) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists PTGER4, OXER1, RXFP4 PTGER4 1/4885TAS1R3 2373/4885TAS1R1 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.